MESO Mesoblast Limited
Price Chart
Executive Summary
Mesoblast received FDA clearance to proceed directly into a registrational trial for Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), a rare and fatal muscle-wasting disease affecting ~15,000 children in the U.S. The Phase 3 trial will enroll 76 patients aged 5–9, with primary endpoint of time-to-stand at nine months.
Actionable Insight
This direct path to a registrational trial without a required Phase 2 is highly unusual and de-risks development. Traders should monitor trial initiation and patient enrollment trends; success could position Ryoncil® as a first-in-class anti-inflammatory therapy for DMD, significantly expanding its market potential beyond SR-aGvHD.
Key Facts
- FDA granted IND clearance for a registrational trial of Ryoncil® in Duchenne muscular dystrophy (DMD).
- Trial will enroll 76 pediatric patients (ages 5–9), randomized to Ryoncil® or placebo, with time-to-stand at 9 months as the primary endpoint.
- Ryoncil® is already FDA-approved for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, supporting its safety profile.
- Mesoblast is partnering with Parent Project Muscular Dystrophy (PPMD) and the Duchenne Registry for patient identification and trial awareness.
Financial Impact
Potential blockbuster expansion into a new pediatric indication with no approved disease-modifying therapies targeting inflammation in DMD.
Risk Factors
- Clinical failure in the registrational trial despite strong preclinical data.
- Limited sample size (76 patients) may raise concerns about statistical power.
- Competition from gene therapies and exon-skipping drugs targeting dystrophin restoration.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
5w ago
|
Press Release
| $15.67 $15.40 | ▼ −1.72% | ▼ −6.95% | $13.80 (−11.93%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $15.55 $14.76 | ▼ −5.08% | ▼ −11.13% | $13.80 (−11.25%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $15.75 $14.44 | ▼ −8.32% | ▼ −14.36% | $13.80 (−12.38%) |
|
Apr 10, 2026
8w ago
|
Press Release
| $14.70 $14.51 | ▼ −1.29% | ▼ −9.02% | $13.80 (−6.12%) |
|
Apr 8, 2026
8w ago
|
Press Release
| $13.92 $15.79 | ▲ +13.43% | ▲ +4.89% | $13.80 (−0.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access